IP Library › Granted Patent US 10,662,241
Granted Patent B1
US 10,662,241 · App. 16/596,723 · Granted May 26, 2020

HER3 antigen-binding molecules

Inventors: Jerome Douglas Boyd-Kirkup (Singapore, SG); Piers Ingram (Singapore, SG); Dipti Thakkar (Singapore, SG); Zhihao Wu (Singapore, SG); Konrad Paszkiewicz (Singapore, SG); Vicente Sancenon (Singapore, SG); Siyu Guan (Singapore, SG)
Assignee: Hummingbird Bioscience Holdings Pte. Ltd.
C07K16/28C07K16/32C07K2317/24C07K2317/522C07K2317/524C07K2317/526C07K2317/565C07K2317/72C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,241
App. No.
16/596,723
Granted
May 26, 2020
Kind
B1
Abstract

HER3 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the HER3 antigen-binding molecules.

Claims (105)

1. An antigen-binding molecule that specifically binds to HER3, comprising:

(i) a heavy chain variable (VH) region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

2. The antigen-binding molecule according to claim 1 , wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

3. The antigen-binding molecule according to claim 1 , wherein the antigen-binding molecule comprises:

a VH region having the following framework regions (FRs):

HC-FR1 having the amino acid sequence of SEQ ID NO:53

HC-FR2 having the amino acid sequence of SEQ ID NO:59

HC-FR3 having the amino acid sequence of SEQ ID NO:66

HC-FR4 having the amino acid sequence of SEQ ID NO:71.

4. The antigen-binding molecule according to claim 1 , wherein the antigen-binding molecule comprises:

a VL region having the following framework regions (FRs):

LC-FR1 having the amino acid sequence of SEQ ID NO:104

LC-FR2 having the amino acid sequence of SEQ ID NO:110

LC-FR3 having the amino acid sequence of SEQ ID NO:120

LC-FR4 having the amino acid sequence of SEQ ID NO:125.

5. The antigen-binding molecule according to claim 1 , wherein the antigen-binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:171.

6. The antigen-binding molecule according to claim 1 , wherein the antigen-binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO:177.

7. A nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule that specifically binds to HER3, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

8. The nucleic acid or plurality of nucleic acids according to claim 7 , wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

9. The nucleic acid or plurality of nucleic acids according to claim 7 , wherein the antigen-binding molecule comprises:

a VH region having the following framework regions (FRs):

HC-FR1 having the amino acid sequence of SEQ ID NO:53

HC-FR2 having the amino acid sequence of SEQ ID NO:59

HC-FR3 having the amino acid sequence of SEQ ID NO:66

HC-FR4 having the amino acid sequence of SEQ ID NO:71.

10. The nucleic acid or plurality of nucleic acids according to claim 7 , wherein the antigen-binding molecule comprises:

a VL region having the following framework regions (FRs):

LC-FR1 having the amino acid sequence of SEQ ID NO:104

LC-FR2 having the amino acid sequence of SEQ ID NO:110

LC-FR3 having the amino acid sequence of SEQ ID NO:120

LC-FR4 having the amino acid sequence of SEQ ID NO:125.

11. The nucleic acid or plurality of nucleic acids according to claim 7 , wherein the antigen-binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:171.

12. The nucleic acid or plurality of nucleic acids according to claim 7 , wherein the antigen-binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO:177.

13. A cell comprising a nucleic acid, or a plurality of nucleic acids, encoding an antigen-binding molecule that specifically binds to HER3, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

14. The cell according to claim 13 , wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

15. The cell according to claim 13 , wherein the antigen-binding molecule comprises:

a VH region having the following framework regions (FRs):

HC-FR1 having the amino acid sequence of SEQ ID NO:53

HC-FR2 having the amino acid sequence of SEQ ID NO:59

HC-FR3 having the amino acid sequence of SEQ ID NO:66

HC-FR4 having the amino acid sequence of SEQ ID NO:71.

16. The cell according to claim 13 , wherein the antigen-binding molecule comprises:

a VL region having the following framework regions (FRs):

LC-FR1 having the amino acid sequence of SEQ ID NO:104

LC-FR2 having the amino acid sequence of SEQ ID NO:110

LC-FR3 having the amino acid sequence of SEQ ID NO:120

LC-FR4 having the amino acid sequence of SEQ ID NO:125.

17. The cell according to claim 13 , wherein the antigen-binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:171.

18. The cell according to claim 13 , wherein the antigen-binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO:177.

19. A method of treating a cancer in a subject, comprising administering to a subject a therapeutically effective amount of an antigen-binding molecule that specifically binds to HER3, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:41

HC-CDR2 having the amino acid sequence of SEQ ID NO:45

HC-CDR3 having the amino acid sequence of SEQ ID NO:48; and

(ii) a light chain variable (VL) region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:88

LC-CDR2 having the amino acid sequence of SEQ ID NO:92

LC-CDR3 having the amino acid sequence of SEQ ID NO:95.

20. The method according to claim 19 , wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:36; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:83.

21. The method according to claim 19 , wherein the antigen-binding molecule comprises:

a VH region having the following framework regions (FRs):

HC-FR1 having the amino acid sequence of SEQ ID NO:53

HC-FR2 having the amino acid sequence of SEQ ID NO:59

HC-FR3 having the amino acid sequence of SEQ ID NO:66

HC-FR4 having the amino acid sequence of SEQ ID NO:71.

22. The method according to claim 19 , wherein the antigen-binding molecule comprises:

a VL region having the following framework regions (FRs):

LC-FR1 having the amino acid sequence of SEQ ID NO:104

LC-FR2 having the amino acid sequence of SEQ ID NO:110

LC-FR3 having the amino acid sequence of SEQ ID NO:120

LC-FR4 having the amino acid sequence of SEQ ID NO:125.

23. The method according to claim 19 , wherein the antigen-binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:171.

24. The method according to claim 19 , wherein the antigen-binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO:177.

25. The method according to claim 19 , wherein the cancer is selected from: a cancer comprising cells expressing an EGFR family member, a cancer comprising cells expressing HER3, a solid tumor, breast cancer, breast carcinoma, ductal carcinoma, gastric cancer, gastric carcinoma, gastric adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal adenocarcinoma, head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), lung cancer, lung adenocarcinoma, squamous cell lung carcinoma, ovarian cancer, ovarian carcinoma, ovarian serous adenocarcinoma, kidney cancer, renal cell carcinoma, renal clear cell carcinoma, renal cell adenocarcinoma, renal papillary cell carcinoma, pancreatic cancer, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, cervical cancer, cervical squamous cell carcinoma, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma, liver cancer, hepatocellular carcinoma, cholangiocarcinoma, uterine cancer, uterine corpus endometrial carcinoma, thyroid cancer, thyroid carcinoma, pheochromocytoma, paraganglioma, bladder cancer, bladder urothelial carcinoma, prostate cancer, prostate adenocarcinoma, sarcoma and thymoma.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2022
From: HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED
To: HUMMINGBIRD BIOSCIENCE PTE. LTD.
Reel/Frame 059519/0410 →
CHANGE OF NAME Recorded Jul 12, 2021
From: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.
To: HUMMINGBIRD BIOSCIENCE HOLDINGS LIMITED
Reel/Frame 056832/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2020
From: BOYD-KIRKUP, JEROME DOUGLAS; THAKKAR, DIPTI; INGRAM, PIERS; PASZKIEWICZ, KONRAD; WU, ZHIHAO; SANCENON, VICENTE; GUAN, SIYU
To: HUMMINGBIRD BIOSCIENCE HOLDINGS PTE. LTD.
Reel/Frame 051753/0101 →
Continuity (1)
Continuation PCTEP2019058035 · Mar 29, 2019
Cited By (3)
US 12,528,877 US 12,551,584 US 12,721,915